Showing results (1-10 of 345) with videos related to
Sort By:
Pageof 35
Clinical Lymphoma, Myeloma & Leukemia|October 13, 2020
Chimeric Antigen Receptor T-cell Therapy for Multiple MyelomaShebli Atrash, Syed Abbas Ali, Saad Z UsmaniLeukemia & Lymphoma|July 7, 2020
Management of newly diagnosed transplant ineligible multiple myelomaShebli Atrash, Manisha Bhutani, Barry Paul, et al.Expert Opinion on Biological Therapy|August 5, 2020
Daratumumab subcutaneous formulation for the treatment of multiple myelomaBarry Paul, Issam Hamadeh, Shebli Atrash, et al.Expert Review of Hematology|July 14, 2020
An evaluation of subcutaneous daratumumab for the treatment of multiple myelomaBarry Paul, Shebli Atrash, Manisha Bhutani, et al.Leukemia|November 29, 2019
Extramedullary multiple myelomaManisha Bhutani, David M Foureau, Shebli Atrash, et al.Oncotargets and Therapy|April 5, 2021
A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and LymphomaShebli Atrash, Tamara K MoyoOncotarget|September 20, 2012
Second primary malignancies and myeloma therapy: fad or fact?Saad Z UsmaniClinical Lymphoma, Myeloma & Leukemia|December 19, 2020
Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based RegimensJai N Patel, Myra Robinson, Megan Jagosky, et al.Clinical Lymphoma, Myeloma & Leukemia|July 15, 2020
Evaluation of Montelukast for the Prevention of Infusion-related Reactions With DaratumumabDonald C Moore, Justin R Arnall, Daniel L Thompson, et al.Clinical Lymphoma, Myeloma & Leukemia|February 8, 2024
SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMMEric Jurgens, Saad Z UsmaniPageof 35